6-(苄氧基)-2-萘硼酸 | 152915-83-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-(苄氧基)-2-萘硼酸
• 英文名称: (6-(benzyloxy)naphthalen-2-yl)boronic acid
• 英文别名: 6-(benzyloxy)naphthalen-2-ylboronic acid；6-benzyloxy-2-naphthaleneboronic acid；6-benzyloxy-2-naphthylboronic acid；(6-phenylmethoxynaphthalen-2-yl)boronic acid
• CAS: 152915-83-8
• 化学式: C₁₇H₁₅BO₃
• 分子量: 278.115
• InChiKey: ZVHAZMUBLCEMGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S37/39
• 储存条件：
  存储条件：2-8°C，密封保存，并确保环境干燥。

SDS

Name:	6-(Benzyloxy)-2-naphthylboronic acid 97% Material Safety Data Sheet
Synonym:
CAS:	152915-83-8

Section 1 - Chemical Product MSDS Name:6-(Benzyloxy)-2-naphthylboronic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
152915-83-8	6-(Benzyloxy)-2-naphthylboronic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 152915-83-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H15BO3
Molecular Weight: 278.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, oxides of boron.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 152915-83-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-(Benzyloxy)-2-naphthylboronic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 152915-83-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 152915-83-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 152915-83-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(苄氧基)-2-萘硼酸 在 sodium hydroxide 、 四(三苯基膦)钯 、 草酰氯 、 sodium carbonate 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 4.0h， 生成 3-(2-((6-(benzyloxy)naphthalen-2-yl)methyl)phenyl)-N-(5-bromo-2-methoxyphenylsulfonyl)acrylamide
  参考文献：
  名称：

  Comparison between two classes of selective EP3 antagonists and their biological activities

  摘要：

  Two different series of very potent and selective EP3 antagonists have been reported: a novel series of ortho-substituted cinnamic acids [Belley, M., Gallant, M., Roy, B., Houde, K., Lachance, N., Labelle, M., Trimble, L., Chauret, N., Li, C., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Greig, G. M., Slipetz, D., Metters, K. M., Gordon, R., Chan, C. C., Zamboni, R. J. Bioorg. Med. Chem. Lett. 2005, 15, 527] and the acylsulfonamides of ortho-(arylmethyl)cinnamates. [(a) Juteau, H., Gareau, Y., Labelle, M., Sturino, C. F., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Metters, K. M. Bioorg. Med. Chem. 2001, 9, 1977; (b) Juteau, H., Gareau, Y., Labelle, M., Lamontagne, S., Tremblay, N., Carriere, M.-C., Denis, D., Sawyer, N., Metters, K. M. Bioorg. Med. Chem. Lett. 2001, 11, 747] The structural differences between the two series, along with their biological activity in vivo, in vitro, and metabolism, are analyzed. Some of those compounds, including hybrids containing the best structural features of both series, possess K-i as low as 0.6 nM on the EP3 receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.025
• 作为产物：
  描述：

  2-苄氧基-6-溴萘 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 6-(苄氧基)-2-萘硼酸
  参考文献：
  名称：

  Comparison between two classes of selective EP3 antagonists and their biological activities

  摘要：

  Two different series of very potent and selective EP3 antagonists have been reported: a novel series of ortho-substituted cinnamic acids [Belley, M., Gallant, M., Roy, B., Houde, K., Lachance, N., Labelle, M., Trimble, L., Chauret, N., Li, C., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Greig, G. M., Slipetz, D., Metters, K. M., Gordon, R., Chan, C. C., Zamboni, R. J. Bioorg. Med. Chem. Lett. 2005, 15, 527] and the acylsulfonamides of ortho-(arylmethyl)cinnamates. [(a) Juteau, H., Gareau, Y., Labelle, M., Sturino, C. F., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Metters, K. M. Bioorg. Med. Chem. 2001, 9, 1977; (b) Juteau, H., Gareau, Y., Labelle, M., Lamontagne, S., Tremblay, N., Carriere, M.-C., Denis, D., Sawyer, N., Metters, K. M. Bioorg. Med. Chem. Lett. 2001, 11, 747] The structural differences between the two series, along with their biological activity in vivo, in vitro, and metabolism, are analyzed. Some of those compounds, including hybrids containing the best structural features of both series, possess K-i as low as 0.6 nM on the EP3 receptor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.025

文献信息

• Synthesis of non-<i>C</i>₂ symmetrical NOBIN-type biaryls through a cascade <i>N</i>-arylation and [3,3]-sigmatropic rearrangement from <i>O</i>-arylhydroxylamines and diaryliodonium salts
  作者：Fengting Liu、Min Wang、Jiatong Qu、Haifeng Lu、Hongyin Gao

  DOI：10.1039/d1ob00636c

  日期：——

  We developed herein a regioselective construction of non-C2 symmetrical NOBIN-type biaryls through a cascade N-arylation and [3,3]-sigmatropic rearrangement from O-arylhydroxylamines and diaryliodonium salts under mild conditions. The employment of copper salt could inhibit the further O-arylation of the newly formed biaryl products, otherwise, O-arylated NOBIN-type products were furnished in moderate

  我们在此开发了在温和条件下通过级联N-芳基化和O-芳基羟胺和二芳基碘鎓盐的[3,3]-σ迁移重排非C 2对称NOBIN型联芳基的区域选择性构建。铜盐的使用可以抑制新形成的联芳基产物的进一步O-芳基化，否则， O-芳基化NOBIN型产品以中等至良好的分离产率提供。该协议的产品可以进一步转化为高价值的功能分子和杂环。
• [¹⁸F]CuCF₃: A [¹⁸F]Trifluoromethylating Agent for Arylboronic Acids and Aryl Iodides
  作者：Pavel Ivashkin、Gérald Lemonnier、Jonathan Cousin、Vincent Grégoire、Daniel Labar、Philippe Jubault、Xavier Pannecoucke

  DOI：10.1002/chem.201403630

  日期：2014.7.28

  Positron emission tomography has emerged as the leading method for medical imaging with fluorine‐18 as the most widely used radioactive isotope. Here we report a semi‐automated method for the preparation of valuable [18F]trifluoromethylcopper, as well as its use for the radiosynthesis of [18F]trifluoromethylarenes and heteroarenes. Mild conditions of [18F]trifluoromethylation make this method particularly

  正电子发射断层扫描已经成为医学成像的主要方法，其中氟18是最广泛使用的放射性同位素。在这里，我们报告了一种半自动化的方法，用于制备有价值的[ 18 F]三氟甲基铜，及其用于[ 18 F]三氟甲基芳烃和杂芳烃的放射性合成。[ 18 F]三氟甲基化的温和条件使该方法特别适用于与药理相关的[ 18 F]三氟甲基芳烃和杂芳烃的放射性合成。
• Fluoroform synthesis and uses thereof in the preparation of trifluoromethylated compounds
  申请人：Institut National des Sciences Appliquées de Rouen (INSA)

  公开号：EP2784055A1

  公开（公告）日：2014-10-01

  The present invention relates to a process to prepare fluoroform (CHF3), notably radio labelled with fluorine-18, comprising a substitution reaction between CHAF2 and a fluoride salt, wherein A represents or as well as a process to prepare a composition comprising copper-based or silver-based trifluoromethylated reagents using notably the fluoroform thus prepared and the use of a composition comprising copper-based trifluoromethylated reagents or a mixture comprising a copper salt and a composition comprising silver-based trifluoromethylated reagents as a trifluoromethylating agent, notably radio labelled with fluorine-18.

  本发明涉及一种制备氟甲烷（CHF3）的方法，特别是用氟-18进行放射标记，包括CHAF2和氟化物盐之间的取代反应，其中A代表或，以及制备含铜或含银三氟甲基试剂的方法，特别是使用制备的氟甲烷，以及将含铜三氟甲基试剂或包含铜盐和含银三氟甲基试剂的混合物作为三氟甲基化试剂的用途，特别是用氟-18进行放射标记。
• Comparison between two classes of selective EP3 antagonists and their biological activities
  作者：Michel Belley、Chi Chung Chan、Yves Gareau、Michel Gallant、Hélène Juteau、Karine Houde、Nicolas Lachance、Marc Labelle、Nicole Sawyer、Nathalie Tremblay、Sonia Lamontagne、Marie-Claude Carrière、Danielle Denis、Gillian M. Greig、Deborah Slipetz、Robert Gordon、Nathalie Chauret、Chun Li、Robert J. Zamboni、Kathleen M. Metters

  DOI：10.1016/j.bmcl.2006.08.025

  日期：2006.11

  Two different series of very potent and selective EP3 antagonists have been reported: a novel series of ortho-substituted cinnamic acids [Belley, M., Gallant, M., Roy, B., Houde, K., Lachance, N., Labelle, M., Trimble, L., Chauret, N., Li, C., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Greig, G. M., Slipetz, D., Metters, K. M., Gordon, R., Chan, C. C., Zamboni, R. J. Bioorg. Med. Chem. Lett. 2005, 15, 527] and the acylsulfonamides of ortho-(arylmethyl)cinnamates. [(a) Juteau, H., Gareau, Y., Labelle, M., Sturino, C. F., Sawyer, N., Tremblay, N., Lamontagne, S., Carriere, M.-C., Denis, D., Metters, K. M. Bioorg. Med. Chem. 2001, 9, 1977; (b) Juteau, H., Gareau, Y., Labelle, M., Lamontagne, S., Tremblay, N., Carriere, M.-C., Denis, D., Sawyer, N., Metters, K. M. Bioorg. Med. Chem. Lett. 2001, 11, 747] The structural differences between the two series, along with their biological activity in vivo, in vitro, and metabolism, are analyzed. Some of those compounds, including hybrids containing the best structural features of both series, possess K-i as low as 0.6 nM on the EP3 receptor. (c) 2006 Elsevier Ltd. All rights reserved.